. Author manuscript; available in PMC: 2021 Jul 15.

Published in final edited form as: Lancet Diabetes Endocrinol. 2017 Jan 6;5(3):165–173. doi: 10.1016/S2213-8587(16)30315-1

Table 2.

Prevalence, Remission, and Incidence of Comorbid Conditions.

	Baseline		FABS5
	Prevalence		Prevalence		Remission^b	Incidence^c
	Observed no. of participants / total no. (%)	Model-estimated^a Percentage (95% CI)	Observed no. of participants / total no. (%)	Model-estimated^a Percentage (95% CI)	Observed no. of participants / total no. (%)	Observed Percentage (95% CI)
Diabetes	9/56 (16.1%)^a	16.1% (8.5,28.3)	1/55 (1.8%)^b	1.8% (0.2,12.0)	7/8 (87.5%)^c	0/45 (0%)^a
Dyslipidemia	48/56 (85.7%)^a	85.7% (73.8,92.8)	21/55 (38.2%)^b	38.2% (26.3,51.7)	29/45 (64.4%)^b	4/8 (50.0%)
Hypertension	27/57 (47.4%)^c	47.4% (34.7,60.4)	9/55 (16.4%)^b	16.4% (8.7,28.7)	19/25 (76.0%)^a	3/29 (10.3%)^c

Generalized mixed models were used to calculate the modeled results.

Remission was calculated as the number of participants (with sufficient data to define comorbidity state) who do not have the condition at long-term visit divided by the number of participants (with sufficient data to define comorbidity state) who had the condition at baseline.

Incidence was calculated as the number of participants (with sufficient data to define comorbidity state) who have the condition at long-term visit divided by the number of participants (with sufficient data to define comorbidity state) who did not have the condition at baseline.